



July 1, 2013

Orthofix Announces Full Market Release and Launch of Trinity® ELITE™

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today in collaboration with the Musculoskeletal Transplant Foundation (MTF) the full market release of Trinity® ELITE™ Allograft with Viable Cells and VersaShield™ Amniotic Membrane tissue forms through both of its Spine Fixation and U.S. Extremity Fixation distribution channels. Trinity ELITE provides the unique feature of being fully moldable by the user, a key distinction of the proprietary technology that MTF developed.



Dr. Peter M. Shedden, MSc., M.D., FRCS(C), FACS, FAANS, of the Greater Houston Neurosurgery Center in The Woodlands, Texas and a member of the Company's medical education team, stated, "In my initial usage of Trinity ELITE, I have been extremely satisfied with the ability to pack more graft material into a disc space during a posterior lumbar interbody fusion procedure, as well as posterior laterally. In addition, this novel allograft represents a new option for surgeons who want to apply a cell-based allograft to the lateral gutter and lay it flat along the transverse process."

Orthofix President and Chief Executive Officer Brad Mason noted, "We are very excited about the initial feedback from the early adopters, which has been universally and extremely positive, as it confirms Trinity ELITE overcomes current challenges in graft containment and handling of cell-based tissue forms. Orthofix has long maintained its commitment to co-developing and commercializing such exciting technology with MTF, and we plan to continue being innovators in this space."

Chief Executive Officer of the Musculoskeletal Transplant Foundation Bruce Stroeve commented, "Over the last five years, the MTF/Orthofix partnership has proven to be a successful endeavor providing a new, viable cell tissue form to tissue recipients. We are

Orthofix Announces Full Market Release and Launch of Trinity ELITE (Photo: Business Wire)

pleased to release our newest innovation, Trinity ELITE. Trinity ELITE is the first fully moldable allograft with viable cells. This next generation allograft is the first cell-based offering of its kind designed to provide an enhanced handling experience and greatly improved graft containment properties."

Trinity ELITE, a third generation allograft with viable cells, provides surgeons with a unique alternative to autograft, the standard for bone grafting. Trinity ELITE builds on the exemplary safety profile of more than 75,000 Trinity Evolution® procedures. Trinity ELITE offers an enhanced handling experience, while providing a viable grafting alternative.

The full market release of Trinity ELITE includes the launch into both spinal and extremity applications and is available in four different quantities.

About Orthofix:

Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative orthopedic solutions that drive value for patients, surgeons, and providers. Orthofix's products are widely distributed around

the world to surgeons and patients via Orthofix's sales representatives and its subsidiaries, and via collaborations with other leading orthopedic product companies. In addition, Orthofix is collaborating on R&D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, and Texas Scottish Rite Hospital for Children. For more information about Orthofix, please visit www.orthofix.com.

About the Musculoskeletal Transplant Foundation (MTF):

The Musculoskeletal Transplant Foundation, the nation's leading tissue bank, changes lives by connecting donors with surgeons and transplant recipients. As a non-profit service organization, MTF is dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. Since its inception in 1987, MTF has recovered tissue from more than 100,000 donors and distributed over 5 million grafts for transplantation. For more information, please visit MTF's website at www.mtf.org.

Photos/Multimedia Gallery Available: <http://www.businesswire.com/multimedia/home/20130701005222/en/>

Orthofix International N.V.
Mark Quick, 214-937-2924
Director of Investor Relations and Business Development
markquick@orthofix.com

Source: Orthofix International N.V.

News Provided by Acquire Media